Laurel Wealth Advisors (California)’s Galectin Therapeutics GALT Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,600	Closed	-$85K	–	410
2019 Q1	$85K	Hold	16,600	–	–	0.02%	393
2018 Q4	$56K	Hold	16,600	–	–	0.02%	346
2018 Q3	$99K	Hold	16,600	–	–	0.02%	394
2018 Q2	$105K	Sell	16,600 -4,800	-22%	-$23.4K	0.03%	376
2018 Q1	$101K	Buy	+21,400	New	+$99.7K	0.03%	347
2017 Q4	–	Sell	-16,000	Closed	-$34K	–	349
2017 Q3	$34K	Hold	16,000	–	–	0.01%	321
2017 Q2	$39K	Buy	16,000 +1,000	+7%	+$2.66K	0.01%	299
2017 Q1	$34K	Buy	15,000 +5,000	+50%	+$7.54K	0.01%	280
2016 Q4	$9K	Buy	+10,000	New	+$8.89K	﹤0.01%	275

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Laurel Wealth Advisors (California)'s GALT Position: Q2 2019 in Review

Laurel Wealth Advisors (California) sold out of Galectin Therapeutics (GALT) in Q2 2019, closing a stake of 16,600 shares — an estimated $85K sold.

Laurel Wealth Advisors (California) first reported a position in GALT in Q4 2016 and held it in 9 quarters. The position peaked at $105K in Q2 2018. 76 funds tracked by Wall St. Rank hold GALT as of Q2 2019.

Laurel Wealth Advisors (California) reported no remaining Galectin Therapeutics position as of Q2 2019 after selling out during the quarter.
Laurel Wealth Advisors (California) sold 16,600 Galectin Therapeutics shares in Q2 2019, an estimated $85K.
Laurel Wealth Advisors (California) first reported a position in Galectin Therapeutics in Q4 2016 and held it in 9 quarters.
Laurel Wealth Advisors (California)'s Galectin Therapeutics position peaked at $105K in Q2 2018.
76 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2019.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q2 2019, filed 13 Aug 2019.